Lu Chi-Hua, Su Hsuan-Yun, Falls Zackary, Jacobs David M, Zhang Qiuyi, Gibson Walter, Jette Gail, Paul Debanjan, Elkin Peter L, Leonard Kenneth E, Bednarczyk Edward M
J Am Pharm Assoc (2003). 2025 Jan-Feb;65(1):102258. doi: 10.1016/j.japh.2024.102258. Epub 2024 Sep 27.
The increase in alcohol use problems and opioid use disorder (OUD) highlights the need for research on effective medication treatments for patients with dual diagnoses.
This study analyzed trends and social disparities in prescribing OUD medications for patients who initially had alcohol use problems and later received their first OUD diagnosis.
This study used merged data from the New York State Office of Addiction Services and Supports and the Medicaid to analyze individuals aged 18 years and older who initially had primary alcohol use problems and later had OUD for the first time between 2005 and 2018. It examined the rates of new buprenorphine and naltrexone prescriptions across various demographic and socioeconomic groups.
Among 27,029 clients, the average rate of new buprenorphine was 64.23 per 1000 clients (95% CI 61.30-67.15), with upward trends. The 18-35 age group had the highest buprenorphine utilization (111.48 per 1000 clients) and highest increase rates compared with other age groups. The white non-Hispanic group had the highest rates of buprenorphine (119.23 per 1000 clients) and showed larger increase over time compared with other race or ethnicity groups. Disabled patients showed slower increasing rates of buprenorphine than other groups. Upward trends were observed in naltrexone. All observed differences were statistically significant (P < 0.05).
Trends showed increased use of OUD medications, with varying rates of buprenorphine utilization across different ages, races, and employment statuses. Despite this, the rates of receiving new buprenorphine remained low, suggesting a need for innovative methods to expand access to treatments.
酒精使用问题和阿片类物质使用障碍(OUD)的增加凸显了对双重诊断患者有效药物治疗进行研究的必要性。
本研究分析了最初有酒精使用问题且后来首次被诊断为OUD的患者在开具OUD药物方面的趋势和社会差异。
本研究使用了纽约州成瘾服务与支持办公室和医疗补助计划的合并数据,以分析2005年至2018年期间18岁及以上最初有原发性酒精使用问题且后来首次出现OUD的个体。研究考察了不同人口统计学和社会经济群体中新的丁丙诺啡和纳曲酮处方率。
在27029名客户中,新的丁丙诺啡平均处方率为每1000名客户64.23例(95%置信区间61.30 - 67.15),呈上升趋势。18 - 35岁年龄组的丁丙诺啡使用率最高(每1000名客户111.48例),与其他年龄组相比增长率也最高。非西班牙裔白人组的丁丙诺啡使用率最高(每1000名客户119.23例),与其他种族或族裔群体相比随时间的增长幅度更大。残疾患者的丁丙诺啡增长率低于其他群体。纳曲酮呈上升趋势。所有观察到的差异均具有统计学意义(P < 0.05)。
趋势表明OUD药物的使用有所增加,不同年龄、种族和就业状况的丁丙诺啡使用率各不相同。尽管如此,新的丁丙诺啡接受率仍然较低,这表明需要创新方法来扩大治疗的可及性。